Pharma Exclusives Pressreleases
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Friday, June 05, 2026Gilead Sciences Inc Nasdaq GILD and Lakefront Biotherapeutics NV Euronext Nasdaq LKFT today announced the successful completion of the previously announced acquisition
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Thursday, June 04, 2026Biogen Inc Nasdaq BIIB announced today that the US Food and Drug Administration FDA has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular atrophy SMA Breakthrough
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
Wednesday, April 22, 2026Moderna Inc today announced that the first participants in the US and UK have been dosed in a Phase study of the Companys investigational mRNAbased H pandemic influenza vaccine candidate mRNA
Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology
Tuesday, April 21, 2026Crown Bioscience a global contract research organization CRO and a JSR Life Sciences company today announced a strategic partnership with Turbine a leading virtual biology company to advance translational oncology
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Monday, April 20, 2026Biogen Inc Nasdaq BIIB and TJ Biopharma TJ Bio today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bios exclusive rights
Thermo Fisher Scientific Launches Applied Biosystems™ PowerFlex™ Thermal Cycler to Advance PCR Flexibility and Productivity
Thursday, April 16, 2026Thermo Fisher Scientific Inc the world leader in serving science today announced the Applied Biosystems PowerFlex Thermal Cycler a nextgeneration polymerase chain reaction PCR instrument designed
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Tuesday, March 31, 2026Eli Lilly and Company and Centessa Pharmaceuticals plc Nasdaq CNTA a clinicalstage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Monday, March 30, 2026Biogen Inc Nasdaq BIIB today announced that the High Dose Regimen of SPINRAZA nusinersen which is comprised of mg mL and mg mL doses was approved by the US Food and Drug Administration
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Tuesday, March 24, 2026Gilead Sciences Inc Nasdaq GILD announced today it has entered into a definitive agreement to acquire Ouro Medicines a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases
Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.
Tuesday, March 24, 2026Thermo Fisher Scientific Inc NYSE TMO the world leader in serving science today announced the completion of its acquisition of Clario Holdings Inc a leading provider of endpoint data solutions for clinical trials for billion in cash plus potential a...
